Ozempic vs Wegovy: Same Molecule, Different Approved Use

They contain the same active ingredient — semaglutide — made by the same manufacturer (Novo Nordisk), but they are two different FDA-approved medications. Ozempic is indicated for type 2 diabetes at doses up to 2 mg, while Wegovy is indicated for chronic weight management at doses up to 2.4 mg.

The core difference is the FDA-approved indication and the maximum dose: Ozempic for type 2 diabetes (up to 2 mg) and Wegovy for chronic weight management (up to 2.4 mg). They share the same active ingredient and the same GLP-1 receptor agonist mechanism. Which one is appropriate for a given person is a clinical decision made by a licensed provider based on their individual medical profile.

Prescribing decisions and FDA-approved indications differ between the two products, and Weight Method dispenses neither brand. Whether a particular medication is appropriate for an individual is determined by a licensed provider based on that person's health profile and the applicable approved indication.

The side effect profiles are similar since both contain semaglutide. Commonly reported effects include nausea, vomiting, diarrhea, constipation, and abdominal pain. Side effects are typically most noticeable during dose escalation. A licensed provider monitors tolerability for patients in Weight Method's compounded program.

Through Weight Method's subscription program, compounded semaglutide is available at $154/month with an online provider consultation, medical review, dose adjustments, and ongoing support all included in that flat monthly price.